Similar to the melanoma mentioned above, limiting the expression of YTHDF-1 is also used in the treatment of colon cancer and shows a higher survival rate in anti-PD-L1 immunotherapy for colon cancer. Here, YTHDF1 is linked to colonic neoplasm.